EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Emergent BioSolutions Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.36−0.02 (-0.31%)
Close on Oct 19, 2026
- Market cap
- $328.18M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
56.1%−2.6 pts over 5 years
Operating margin
13.5%−14.3 pts over 5 years
Net margin
7.1%−12.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -28.8% | -12.7% | -14.0% | +4.3% | |
| Gross profit | +15.0% | +2.9% | -14.7% | +0.9% | |
| Operating income | – | – | -25.6% | -3.4% | |
| Net income | – | – | -29.7% | -1.8% | |
| EPS, diluted | – | – | -30.4% | -4.1% | |
| Free cash flow | +338.0% | – | -16.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 24.1% | 10.5% | |
| Return on assets | 5.2% | 11.7% | 3.9% | |
| Current ratio | 4.82 | 3.11 | 5.01 | |
| Debt to equity | 0.42 | 0.60 | 1.09 | |
| Net debt to EBITDA | -0.18× | 0.52× | 1.87× | |
| Interest coverage | 13.9× | 14.0× | 1.7× | |
| Inventory turnover | 1.9× | 2.5× | 1.0× | |
| Capex to revenue | 15.6% | 9.0% | 1.9% | |
| Diluted shares | 49M | 54M | 57M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Emergent BioSolutions generated $789.90M from operations and spent $641.20M on capital expenditure, dividends and share buybacks. 67% of that went back into the business.
Generated
$789.90M
Used
$641.20M
Capital expenditure$428.20M67%Dividends$00%Share buybacks$213.00M33%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin7.1%
×Asset turnover0.55×
×Equity multiplier2.69×
=Return on equity, FY202510.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 7.1% | 0.55× | 2.69× | 10.5% |
| FY2024 | -18.3% | 0.65× | 2.84× | -33.7% |
| FY2023 | -72.5% | 0.42× | 2.45× | -74.7% |
| FY2022 | -18.9% | 0.36× | 2.04× | -14.1% |
| FY2021 | 12.4% | 0.61× | 1.91× | 14.3% |
| FY2020 | 19.4% | 0.61× | 2.05× | 24.1% |
| FY2019 | 4.9% | 0.49× | 2.17× | 5.2% |
| FY2018 | 8.0% | 0.47× | 1.72× | 6.5% |
| FY2017 | 14.7% | 0.55× | 1.35× | 11.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$52.60M
- Cash generatingOperating cash flow above zero$170.60M
- Return on assets improvedROA up on the prior year-10.5% → 3.8%
- Earnings backed by cashOperating cash flow above net income$170.60M vs $52.60M
- Less leverageLong-term debt to assets fell47.8% → 43.4%
- Better liquidityCurrent ratio rose3.69 → 5.01
- No dilutionShare count did not rise53M → 57M
- Gross margin improvedGross margin up on the prior year34.72% → 56.09%
- More efficientAsset turnover rose0.57 → 0.53